antiproliferative agent-13

Antiproliferative agent-13 is a compound with antiproliferative activity.

Antimalarial agent 13 (N2-(3-chlorophenyl)-N4-(furan-2-ylmethyl)quinazoline-2,4-diamine) is a potent antimalarial agent.

Antiproliferative agent-16 (Antiproliferative agent-16) is an indolyl hydrazide-hydrazone compound with anticancer activity. Antiproliferative agent-16 exhibits specificity toward breast cancer cells (IC50 of 6.94 μM for MCF-7 cells).

Antiproliferative Agent-27 (Compound 11) is a notable antiproliferative agent that markedly diminishes tumor cell colony formation and induces apoptosis, demonstrating potential for utilization in cancer research [1].

Antiproliferative Agent-39 (Compound 12) effectively inhibits the proliferation of various cancer cell lines, including A549, SNU-638, Col2, HT1080, and MCF-7, with respective IC50 values of 11, 25, 14, 11, and 6.3 μM [1].

Antiproliferative agent-3 (comp 4) exhibits potent growth inhibitory effects against MCF-7 cells with an IC50 of 0.19 nM [1].

Antiproliferative agent-4 showed good anti-proliferative effects on some cancer cells. antiproliferative agent-4 inhibited tumour growth in nude mice and showed low toxicity. antiproliferative agent-4 reduced the mitochondrial membrane potential of EC109 cells and increased Antiproliferative agent-4 reduced the mitochondrial membrane potential of EC109 cells and increased the apoptosis rate and ROS level.

Antiproliferative agent-6 (compound 8a) is a potent antitumor compound exhibiting antiproliferative activity. It inhibits cancer cell lines HCT116, MCF-7, H460, and non-tumor aneuploid immortal keratinocyte HaCaT cells with GI50 values of 0.5 μM, 2 μM, 0.7 μM, and 3.5 μM, respectively.

Antiproliferative agent-26 (compound 4g) shows broad-spectrum activity against leukemia, CNS cancers, melanoma, renal, and breast cancers at 10 μM, inhibits colony formation, induces G1 phase cell cycle arrest at 5 μM, and causes S phase cell cycle arrest at 25 μM [1].

Compound PC-A1 (Antiproliferative agent-48) demonstrates selective antiproliferative activity against triple-negative breast cancer (TNBC) cells [1].

Anticancer agent 13 is a compound derived from dicarboxylic acids and amines, developed for use as an anticancer agent.

Antiproliferative Agent-20 is a potent, orally active anticancer compound exhibiting both antiproliferative and anti-angiogenic activities.

Antiproliferative Agent-11, a selective Ruthenium(II)-Tris-pyrazolylmethane complex, exhibits antiproliferative effects on MCF-7, HeLa, 518A2, HCT116, and RD cancer cell lines with IC50 values of 6, 10, 6.8, 6.7, and 6 μM, respectively. This compound is utilized in cancer research.

Antiproliferative Agent-38 (COM 18), a tetracyclic compound, features a reactive ring nitrogen (likely the quinoline moiety) that resists N-alkylation. Despite its classification, it neither exhibits anti-malarial properties nor inhibits cancer cell proliferation [1].

Antiproliferative agent-37 (compound 10J) inhibits cell proliferation by arresting cells at the G2 M phase of the cell cycle [1].

Antiproliferative agent-22 (compound 2), an anticancer agent, exhibits anti-proliferative effects on MCF-7, MDA-MB-231, and MDA-MB-468 cells, exhibiting IC50 values of 6.2 μM, 3.3 μM, and 3.3 μM respectively [1].

Antitubercular agent-13 (Compound 3d) is an antitubercular compound with MIC values of 0.007 μg mL against MTB H37Rv and 1.851 μg mL against MDR-MTB 16833, respectively, and exhibits metabolic instability [1].

Antiproliferative agent-32 (Compound 1c) impedes phosphorylation in the PI3K Akt mTOR signaling pathway, restricts proliferation of Huh7 and SK-Hep-1 cells, induces apoptosis, and causes mitochondrial damage, making it a potential candidate for hepatocellular carcinoma research [1].

Antiproliferative agent-30 (Compound 8g) exhibits broad-spectrum antiproliferative activity, with IC50 values of 0.054 nM, 0.008 nM, and 0.144 nM against HCT-116, K562, and MV-4-11 cancer cell lines, respectively. It inhibits tubulin assembly, FLT3, and Abl1 kinases and shows vascular-disrupting capabilities. Additionally, it displays an anticancer effect against acute myeloid leukemia (AML) with FLT3-ITD-TKD mutations [1].

Antiproliferative Agent-19, an anti-cancer compound, demonstrates antiproliferative effects by inducing apoptosis in lung cancer cells and causing cell cycle arrest in the G2/M phase.

Compound 5k (Antiproliferative Agent-18) is an antiproliferative agent that exhibits moderate antibacterial and antifungal activities [1].

Antiproliferative agent-7 (compound 8f) is a potent anti-proliferative agent that promotes ROS production and induces apoptosis.

Antiproliferative agent-52 (Compound 4a) exhibits significant antiproliferative activity against four human tumor cell lines (A549, A2780, SKOV3, HCC827), with IC50 values ranging from 5.83 to 8.63 nM. This compound is useful for cancer research.

Antiproliferative Agent-25 (Compound 3s4) is a selective PRMT5 inhibitor displaying an IC50 of 0.11 μM. It elevates hnRNP E1 protein levels and forms hydrogen bond interactions with SAM and the E444 residue of PRMT5. This compound exhibits antiproliferative effects in A549 cells by inducing apoptosis and inhibiting migration, albeit it presents high clearance rates, with half-lives of 21.8 minutes in human liver microsomes and 4.7 minutes in rat liver microsomes [1].

Anti-inflammatory agent 13 is a pentacyclic triterpene compound with a significant inhibitory effect on inflammation models. anti-inflammatory agent 13 has the potential to be used in studies of DAMP or PAMP-induced inflammation.

Antiproliferative agent-15 is a reagent with anticancer activity. Antiproliferative agent-15 showed antiproliferative activity against human colon cancer (HCT116 and HCT15) and brain cancer (LN-229 and GBM-10).

Antileishmanial agent-13, a quinoline-isatin hybrid, functions as an antileishmanial agent targeting the L. Major Leishmania strain through an anti-folate mechanism. This compound exhibits potent inhibition of both the promastigote and amastigote forms, boasting IC50 values of 0.604 μM and 0.508 μM, respectively.

Antiproliferative Agent-10, a ruthenium(II)-tris-pyrazolylmethane complex, functions as an anti-tumor compound by impeding cancer cell growth through the inhibition of mitochondrial calcium uptake.

Antiproliferative Agent-17 exhibits both antimicrobial properties against Gram-positive bacteria and anticancer activity [1].

Antiproliferative agent-23, a microtubule-destabilizing agent (MDA), disrupts the tubulin-microtubule system, leading to apoptosis through a mitochondrion-dependent pathway. This involves downregulation of Bcl-2 protein, upregulation of Bax and Cyt c proteins, and activation of the caspase cascade. Additionally, it induces reactive oxygen species (ROS)-mediated endoplasmic reticulum stress in A549/CDDP cells (cisplatin-resistant cancer cell line) through the PERK/ATF4/CHOP signaling pathway, demonstrating anti-tumor activity [1].

Antiproliferative Agent-10 (Compound 1), a ruthenium(II)-tris-pyrazolylmethane complex, functions as an anti-tumor agent by impeding cancer cell proliferation through the inhibition of mitochondrial calcium uptake [1].

Antiproliferative agent-8 (Compound 5a) is an anti-cancer compound that significantly increases P53 levels.

Antifungal agent 13 demonstrates significant antifungal activity against Sclerotinia sclerotiorum, achieving an EC50 of 1.25 mg/L.

Antiproliferative Agent-41 (Compound 14), classified as indanorine [1], functions as an antiproliferative compound.

Antiproliferative agent-40 (Compound 9) effectively inhibits the proliferation of HT1080 and MCF-7 cancer cells, with IC50 values of 52 μM and 8.2 μM, respectively [1].

Antiproliferative Agent-33 (Compound 2g) serves as an anti-proliferative, antifungal, and antibacterial agent, effectively inhibiting the proliferation of MDA-MB-231 cells (IC50: 16.38 μM), impairing the growth of gram-negative bacteria, and restraining S. faecalis with an MIC of 8 μg/mL [1].

Compound 4b (antitrypanosomal agent 13) is a potent antitrypanosomal with notable trypanocidal and cytotoxic activities, exhibiting GI50 values of 0.18 μM against T. brucei and 8.4 μM for HL-60 [1].

Compound 5f (Antioxidant agent-13) is an antioxidant that demonstrates inhibition of DPPH and FRAP with half maximal inhibitory concentrations (IC50s) of 80.33 µM and 85.69 µM, respectively. Additionally, it inhibits the enzymes lipoxygenase (LOX) and xanthine oxidase (XO) with IC50s of 16.85 µM and 23.01 µM, respectively [1].

Antiproliferative Agent-34 (Compound A14), a multitarget kinase inhibitor, demonstrates IC50 values of 177 nM for EGFR L858R/T790M and 1567 nM for EGFR WT. Additionally, it inhibits JAK2, ROS1, FLT3, FLT4, and PDGFRα with respective IC50s of 30.93 nM, 106.90 nM, 108.00 nM, 226.60 nM, and 42.53 nM. In normoxic conditions, it suppresses the proliferation of H1975 and HCC827 cells with IC50 values below 40 nM, while under hypoxic conditions, its potency increases 4-6 fold, yielding IC50 values less than 10 nM [1].

Antiproliferative agent-5 (compound 4o) irreversibly and significantly inhibits the proliferation of gastric cancer cells, blocks the cell cycle in the G2 M phase, induces ROS accumulation, and activates cellular autophagy. Antiproliferative agent-5 can be used in anti-cancer research.

Antiproliferative Agent-42 (Compound 7m), a dihydrodipyrrolo compound, exhibits antiproliferative activity against the Panc-1 cell line, with an IC 50 of 12.54 μM [1].

Antiproliferative agent-36 is a broad-spectrum anticancer benzothiazolylhydrazone-derived compound that inhibits cell proliferation.